Analysis of CD40 expression in breast cancer and its relation to clinicopathological characteristics

Neoplasma

Volumn 58, Issue 3, 2011, Pages 189-197

  Slobodova, Z ^a   Ehrmann, J ^a   Krejci, V ^a   Zapletalova, J ^a   Melichar, B ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Bcl 2; Breast cancer; CD40 expression; Luminal A subtype

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER STAGING; CELL NUCLEUS; CYTOPLASM; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MEMBRANE; OVERALL SURVIVAL; PATHOLOGY; RELAPSE; AGED; CHEMISTRY; FEMALE; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PROGNOSIS;

ADULT; AGED; ANTIGENS, CD40; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 79961101225     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_03_189     Document Type: Article

References (49)

1. FERLAY J, PARKIN DM, STELIAROVA-FOUCHER E Esti mates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81. doi:10.1016/j.ejca.2009.12.014
2. SØRLIE T, PEROU CM, TIBSHIRANI R, AAS T, GEISLER S et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-74. doi:10.1073/pnas.191367098
3. MUÑOZ M, FERNÁNDEZ-ACEÑERO MJ, MARTÍN S, SCHNEIDER J Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch Gynecol Obstet 2008; 280: 43-8.
4. BRENTON JD, CAREY LA, AHMED AA, CALDAS C Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005; 23: 7350-60. doi:10.1200/JCO.2005.03.3845
5. JANSEN MP, FOEKENS JA, VAN STAVEREN IL, DIRKZWAGER-KIEL MM, RITSTIER K et al. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005; 23: 732-40. doi:10.1200/JCO.2005.05.145
6. SØRLIE T, WANG Y, XIAO C, JOHNSEN H, NAUME B et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006; 7: 127. doi:10.1186/1471-2164-7-127
7. LOI S Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt? Eur J Cancer 2008; 44: 2813-8. doi:10.1016/j.ejca.2008.09.012
8. DAWOOD S, HU R, HOMES MD, COLLINS LC, SCHNITT SJ et al. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat. 2010; 10: 1113-7.
9. CHEANG MC, CHIA SK, VODUC D, GAO D, LEUNG S et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101: 736-50. doi:10.1093/jnci/djp082
10. KATZENELLENBOGEN BS Antiestrogen resistance: mechanisms by which breast cancer cells undermine the effectiveness of endocrine therapy. J Natl Cancer Inst 1991; 83: 1434-5. doi:10.1093/jnci/83.20.1434
11. ROUSSET F, GARCIA E, BANCHEREAU J Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J Exp Med 1991; 173: 705-10. doi:10.1084/jem.173.3.705
12. ALDERSON MR, ARMITAGE RJ, TOUGH TW, STROCKBINE L, FANSLOW WC et al. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993; 178: 669-74. doi:10.1084/jem.178.2.669
13. ZHANG X, KEDL RM, XIANG J CD40 ligation converts TGF-beta-secreting tolerogenic CD4(-)8(-) dendritic cells into IL-12-secreting immunogenic ones. Biochem Biophys Res Commun 2009; 379: 954-8. doi:10.1016/j.bbrc.2008.12.179
14. BALKOW S, LOSER K, KRUMMEN M, HIGUCHI T, ROTHOEFT T et al. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity. Exp Dermatol 2009; 18: 78-87. doi:10.1111/j.1600-0625.2008.00800.x
15. ALEXANDROFF AB, JACKSON AM, PATERSON T, HALEY JL, ROSS JA et al. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol 2000; 37: 515-26. doi:10.1016/S0161-5890(00)00079-1
16. COOKE PW, JAMES ND, GANESAN R, WALLACE M, BURTON A et al. CD40 expression in bladder cancer. J Pathol 1999; 188: 38-43. doi:10.1002/(SICI)1096-9896(199905)188:1<38:: AID-PATH315>3.0.CO;2-B
17. GHAMANDE S, HYLANDER BL, OFLAZOGLU E, LELE S, FANSLOW W et al. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Cancer Res 2001; 61: 7556-62.
18. POSNER MR, CAVACINI LA, UPTON MP, TILLMAN KC, GORNSTEIN ER et al. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res 1999; 5: 2261-70.
19. TONG AW, STONE MJ Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003; 10: 1-13. doi:10.1038/sj.cgt.7700527
20. BROUTY-BOYÉ D, POTTIN-CLÉMENCEAU C, DOUCET C, JASMIN C, AZZARONE B Chemokines and CD40 expression in human fibroblasts. Eur J Immunol 2000; 30: 914-9. doi:10.1002/1521-4141(200003)30:3<914::AID-IMMU914>3.0.CO;2-D
21. HIRANO A, LONGO DL, TAUB DD, FERRIS DK, YOUNG LS et al. Inhibition of human breast carcinoma growth by a soluble recombinant human CD40 ligand. Blood 1999; 93: 2999-3007.
22. LIN-LEE YC, PHAM LV, TAMAYO AT, FU L, ZHOU HJ et al. Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes. J Biol Chem 2006; 281: 18878-87. doi:10.1074/jbc.M513315200
23. TAVASSOLI FA, DEVILEE P, editors. World Health Organization Classification of Tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press, 2003.
24. WOLFF AC, HAMMOND ME, SCHWARTZ JN et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 2007; 131: 18.
25. HARVEY JM, CLARK GM, OSBORNE CK, ALLRED DC Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-81.
26. PALMER DH, HUSSAIN SA, GANESAN R, COOKE PW, WALLACE DM et al. CD40 expression in prostate cancer: a potential diagnostic and therapeutic molecule. Oncol Rep 2004; 12: 679-82.
27. MOGHADDAMI M, COHEN P, STAPLETON AM, BROWN MP CD40 is not detected on human prostate cancer cells by immunohistologic techniques. Urology 2001; 57: 573-8. doi:10.1016/S0090-4295(00)01005-0
28. ISHIKAWA K, MIYAMOTO M, YOSHIOKA T, KATO T, KAJI M et al. Up-regulation of CD40 with juxtacrine activity in human nonsmall lung cancer cells correlates with poor prognosis. Cancer 2008; 113: 530-41. doi:10.1002/cncr.23618
29. KOMI J, LASSILA O Toremifene increases the expression of intercellular adhesion molecule-1 (ICAM-1) on MCF-7 breast cancer cells and Jurkat cells. Scand J Immunol. 2000; 51: 73-8. doi:10.1046/j.1365-3083.2000.00653.x
30. GERALDES P, GAGNON S, HADJADJ S, MERHI Y, SIROIS MG et al. Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: an ERalpha-mediated pathway. Cardiovasc Res. 2006; 71: 566-73. doi:10.1016/j.cardiores.2006.05.015
31. ESTEVA FJ, WANG J, LIN F, MEJIA JA, YAN K et al. CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res 2007; 9: R87. doi:10.1186/bcr1836
32. PINZON-CHARRY A, SCHMIDT CW, LÓPEZ JA The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction. Breast Cancer Res 2006; 8: 402. doi:10.1186/ bcr1386
33. PINZON-CHARRY A, MAXWELL T, MCGUCKIN MA, SCHMIDT C, FURNIVAL C et al. Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Res 2006; 8: R5. doi:10.1186/bcr1361
34. VONDERHEIDE RH Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res 2007; 13: 1083-8. doi:10.1158/1078-0432.CCR-06-1893
35. BEREZNAYA NM, CHEKHUN VF Expression of CD40 and CD40L on tumor cells the role of their interaction and new approach to immunotherapy. Exp Oncol 2007; 29: 2-12.
36. VAUX DL Toward an understanding of the molecular mechanisms of physiological cell death. Proc Natl Acad Sci U S A 1993; 90: 786-9. doi:10.1073/pnas.90.3.786
37. BASU A, HALDAR S The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod 1998; 4: 1099-109. doi:10.1093/molehr/ 4.12.1099
38. YIP KW, REED JC Bcl-2 family proteins and cancer. Oncogene 2008; 27: 6398-406. doi:10.1038/onc.2008.307
39. Zamzami N, Brenner C, Marzo I, Susin SA, KROEMER G Subcellular and submitochondrial mode of action of Bcl-2-like oncoproteins. Oncogene 1998; 16: 2265-82. doi:10.1038/ sj.onc.1201989
40. BATCHELDER AJ, GORDON-WEEKS AN, WALKER RA Altered expression of anti-apoptotic proteins in non-involved tissue from cancer-containing breasts. Breast Cancer Res Treat 2009; 114: 63-9. doi:10.1007/s10549-008-9988-2
41. CALLAGY GM, WEBBER MJ, PHAROAH PD, CALDAS C Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008; 8: 153. doi:10.1186/1471-2407-8-153
42. CALLAGY GM, PHAROAH PD, PINDER SE, HSU FD, NIELSEN TO et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006; 12: 2468-75. doi:10.1158/1078-0432. CCR-05-2719
43. TRERÉ D, MONTANARO L, CECCARELLI C, BARBIERI S, CAVRINI G et al. Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast. Ann Oncol 2007; 18: 1004-14. doi:10.1093/annonc/mdm074
44. KYNDI M, SØRENSEN FB, KNUDSEN H, ALSNER J, OVERGAARD M et al. Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c. Acta Oncol 2008; 47: 608-17. doi:10.1080/02841860802050746
45. ZHOU HJ, PHAM LV, TAMAYO AT, LIN-LEE YC, FU L et al. Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B-cell lymphoma. Blood 2007; 110: 2121-7. doi:10.1182/blood-2007-02-073080
46. LIN SY, MAKINO K, XIA W, MATIN A, WEN Y et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001; 3: 802-8. doi:10.1038/ncb0901-802
47. WELLS A, MARTI U Signalling shortcuts: cell-surface receptors in the nucleus? Nat Rev Mol Cell Biol 2002; 3: 697-702. doi:10.1038/nrm905
48. LANGE A, MILLS RE, LANGE CJ, STEWART M, DEVINE SE et al. Classical nuclear localization signals: definition, function, and interaction with importin alpha. J Biol Chem 2007; 282: 5101-5. doi:10.1074/jbc.R600026200
49. PARKHURST CN, ZAMPIERI N, CHAO MV Nuclear localization of the p75 neurotrophin receptor intracellular domain. J Biol Chem 2010; 285: 5361-8. doi:10.1074/jbc.M109.045054